Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.
13 января 2021 года
18:30
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.
Текст новости:
Title: Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.; Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.
Author, co-author: Devos T.; Devos T.; Verhoef G.; Verhoef G.; Steel E.; Steel E.; Mazure D.; Mazure D.; Lewalle P.; Lewalle P.; Bron D.; Bron D.; Berneman Z.; Berneman Z.; Benghiat FS.; Benghiat FS.; MIneur P.; MIneur P.; Theunissen K.; Theunissen K.; Zachée P.; Zachée P.; Doyen C.; Doyen C.; Put N.; Put N.; LEJEUNE, Marie; LEJEUNE, Marie; Van Eygen K.; Van Eygen K.; Havelange V.; Havelange V.; Reusens M.; Reusens M.; Pluymers W.; Pluymers W.; Peeters K.; Peeters K.
Abstract: Objectives: To assess interruptions/discontinuations of tyrosine kinase inhibitor (TKI) treatment in Belgian patients with
chronic myeloid leukaemia (CML). Methods: This retrospective study included patients with TKI interruptions/discontinuations of ≥4 continuous weeks (no clinical trial context)
between May 2013 and May 2016. Data collection took place
between October 2016 and February 2017. Results: All 60
participants (69 interruptions/discontinuations) had chronic-phase CML and 75% had at least a major molecular response (≥MMR) at interruption/discontinuation. Most interruptions/discontinuations occurred while on imatinib
(36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/
discontinuations occurred due to side effects/intolerance
(46/69; 67%); other reasons included a wish to conceive
(6/69; 9%) and attempts to achieve treatment-free remission
(TFR) (6/69; 9%). Interruptions due to side effects occurred
later for imatinib- or dasatinib-treated patients than for
those on nilotinib or ponatinib. Treatment was re-initiated in
62% (43/69) of cases. Most interruptions caused by side effects/intolerance were followed by treatment changes. All 4
patients with ≥MR 4.5 at interruption/discontinuation and
≥11-month follow-up who had not restarted treatment
maintained the response. Conclusion: Although TKIs are
used for long-term CML treatment, physicians sometimes
recommend interruptions/discontinuations. In this study,
interruptions/discontinuations were mainly caused by side
effects or intolerance, rather than TFR attempts.; Objectives: To assess interruptions/discontinuations of tyrosine kinase inhibitor (TKI) treatment in Belgian patients with
chronic myeloid leukaemia (CML). Methods: This retrospective study included patients with TKI interruptions/discontinuations of ≥4 continuous weeks (no clinical trial context)
between May 2013 and May 2016. Data collection took place
between October 2016 and February 2017. Results: All 60
participants (69 interruptions/discontinuations) had chronic-phase CML and 75% had at least a major molecular response (≥MMR) at interruption/discontinuation. Most interruptions/discontinuations occurred while on imatinib
(36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/
discontinuations occurred due to side effects/intolerance
(46/69; 67%); other reasons included a wish to conceive
(6/69; 9%) and attempts to achieve treatment-free remission
(TFR) (6/69; 9%). Interruptions due to side effects occurred
later for imatinib- or dasatinib-treated patients than for
those on nilotinib or ponatinib. Treatment was re-initiated in
62% (43/69) of cases. Most interruptions caused by side effects/intolerance were followed by treatment changes. All 4
patients with ≥MR 4.5 at interruption/discontinuation and
≥11-month follow-up who had not restarted treatment
maintained the response. Conclusion: Although TKIs are
used for long-term CML treatment, physicians sometimes
recommend interruptions/discontinuations. In this study,
interruptions/discontinuations were mainly caused by side
effects or intolerance, rather than TFR attempts.
Связанные объекты: #A (найти в новостях), #All (найти в новостях).

Текст со страницы (автоматическое получение):
Title :
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.
Language :
Keywords :
[en] Chronic myeloid leukaemia ; Chronic myeloid leukaemia ; Tyrosine kinase inhibitor ; Tyrosine kinase inhibitor ; Treatment interruption/discontinuation ; Treatment interruption/discontinuation ; Molecular response ; Molecular response ; Imatinib ; Imatinib ; Nilotinib ; Nilotinib ; Dasatinib ; Dasatinib ; Ponatinib ; Ponatinib
Abstract :
[en] Objectives: To assess interruptions/discontinuations of tyrosine kinase inhibitor (TKI) treatment in Belgian patients with
chronic myeloid leukaemia (CML). Methods: This retrospective study included patients with TKI interruptions/discontinuations of ≥4 continuous weeks (no clinical trial context)
between May 2013 and May 2016. Data collection took place
between October 2016 and February 2017. Results: All 60
participants (69 interruptions/discontinuations) had chronic-phase CML and 75% had at least a major molecular response (≥MMR) at interruption/discontinuation. Most interruptions/discontinuations occurred while on imatinib
(36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/
discontinuations occurred due to side effects/intolerance
(46/69; 67%); other reasons included a wish to conceive
(6/69; 9%) and attempts to achieve treatment-free remission
(TFR) (6/69; 9%). Interruptions due to side effects occurred
later for imatinib- or dasatinib-treated patients than for
those on nilotinib or ponatinib. Treatment was re-initiated in
62% (43/69) of cases. Most interruptions caused by side effects/intolerance were followed by treatment changes. All 4
patients with ≥MR 4.5 at interruption/discontinuation and
≥11-month follow-up who had not restarted treatment
maintained the response. Conclusion: Although TKIs are
used for long-term CML treatment, physicians sometimes
recommend interruptions/discontinuations. In this study,
interruptions/discontinuations were mainly caused by side
effects or intolerance, rather than TFR attempts.
[en] Objectives: To assess interruptions/discontinuations of tyrosine kinase inhibitor (TKI) treatment in Belgian patients with
chronic myeloid leukaemia (CML). Methods: This retrospective study included patients with TKI interruptions/discontinuations of ≥4 continuous weeks (no clinical trial context)
between May 2013 and May 2016. Data collection took place
between October 2016 and February 2017. Results: All 60
participants (69 interruptions/discontinuations) had chronic-phase CML and 75% had at least a major molecular response (≥MMR) at interruption/discontinuation. Most interruptions/discontinuations occurred while on imatinib
(36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/
discontinuations occurred due to side effects/intolerance
(46/69; 67%); other reasons included a wish to conceive
(6/69; 9%) and attempts to achieve treatment-free remission
(TFR) (6/69; 9%). Interruptions due to side effects occurred
later for imatinib- or dasatinib-treated patients than for
those on nilotinib or ponatinib. Treatment was re-initiated in
62% (43/69) of cases. Most interruptions caused by side effects/intolerance were followed by treatment changes. All 4
patients with ≥MR 4.5 at interruption/discontinuation and
≥11-month follow-up who had not restarted treatment
maintained the response. Conclusion: Although TKIs are
used for long-term CML treatment, physicians sometimes
recommend interruptions/discontinuations. In this study,
interruptions/discontinuations were mainly caused by side
effects or intolerance, rather than TFR attempts.
Permalink :
Автоматическая система мониторинга и отбора информации
Источник
Другие материалы рубрики
ТОП-10 статей
1. 🇨🇳 [Эксклюзивный репортаж]. Китайские конструкторы добились важного прорыва в технологиях ...
2. «Соглашения Артемиды»: как США формируют новый космический альянс
3. Evaluation de la mission de mise en place de programmes de promotion de la santé et de promotion d’un environnement scolaire favorable à la santé - Rapport final
4. 🆕 [Фоторепортаж ИА Синьхуа]. Дипломаты и международные представители посетили мероприятие ...
5. Marcel Broodthaers. Lo sguardo e la pratica allegorica nella contemporaneità (Marcel Broodthaers. Perceptive Glance and Allegorical Practice in Contemporary Art)
6. В 2021 году в космос будут запущены три школьных спутника
7. Россия возобновила переговоры об экспорте ракетных двигателей
8. Черноморский флот пытаются заблокировать в Севастополе
9. The effect of corn straw return on corn production in Northeast China: An integrated regional evaluation with meta-analysis and system dynamics
10. Глава МИД Ирана о полёте бомбардировщиков B-52 ВВС США: Лучше бы вы потратили эти деньги на здравоохранение


Ресурсы